|
|
|
|
|
Print this page
|
|
DXV406
|
(A multi-centre, randomized, parallel group, double-blind, phase IV study to compare the renal effects of non-ionic iso-osmolar contrast medium (IOCM), iodixanol 320mg I/mL (VisipaqueTM), with the non-ionic low osmolar contrast medium (LOCM), iopamidol 300 mg I/mL, in subjects with impaired renal function and diabetes mellitus undergoing multidetector-row helical CT)
|
|
The DXV406 trial is a multi-center trial being conducted at 50 centers in North America and Europe. The trial is sponsored by GE Healthcare. The objective of this trial is to evaluate and compare the effects, efficacy and safety of two different contrast media, iodixanol (VisipaqueTM) and iopamidol on renal function. Patients referred for CT scan with contrast who have been diabetic for at least 1 year and have an elevated serum creatinine (>1.7mg.dl) are eligible for screening.
|
Contant Info
Principal Investigator: Ronald P. Karlsberg, MD
Study Coordinator: : Tracey S. Gerez, BS, MA
Contact number: 310.275.9551
|
|
|
|
|